Eisai Inactive Page Revenue and Competitors
Estimated Revenue & Valuation
- Eisai Inactive Page's estimated annual revenue is currently $876M per year.
- Eisai Inactive Page's estimated revenue per employee is $201,000
Employee Data
- Eisai Inactive Page has 4358 Employees.
- Eisai Inactive Page grew their employee count by 2% last year.
Eisai Inactive Page's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Member Board Directors | Reveal Email/Phone |
2 | Chief Medical Officer, SVP, Head Global Medical Affairs, Neurology | Reveal Email/Phone |
3 | Sr. Executive Assistant to EVP Human Resources, Chief Strategy Officer & Exec Dir Total Rewards | Reveal Email/Phone |
4 | VP Global Clinical Quality Assurance | Reveal Email/Phone |
5 | Head Epilepsy; Executive Director, Clinical Research, Neurology Business Unit | Reveal Email/Phone |
6 | VP, Alzheimer’s Disease Commercial | Reveal Email/Phone |
7 | SVP | Reveal Email/Phone |
8 | Head Discovery | Reveal Email/Phone |
9 | VP, Corporate Planning | Reveal Email/Phone |
10 | Head Clinical Biomarker, Translational Science | Reveal Email/Phone |
Eisai Inactive Page Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $6.6M | 33 | 32% | N/A | N/A |
#2 | $38M | 189 | 6% | N/A | N/A |
#3 | $6.6M | 33 | 22% | N/A | N/A |
#4 | $4180M | 15242 | 1% | $550M | N/A |
#5 | $17.5M | 87 | 50% | N/A | N/A |
#6 | $6.7M | 125 | -37% | $199.6M | N/A |
#7 | $10.9M | 54 | 15% | N/A | N/A |
#8 | $15.3M | 76 | 33% | N/A | N/A |
#9 | $128.6M | 640 | 16% | N/A | N/A |
#10 | $18.7M | 93 | 21% | N/A | N/A |
What Is Eisai Inactive Page?
Thank you for your interest in Eisai Inc. This page is not active, please go to the Eisai US page for the latest job postings and company information.
keywords:N/A
N/A
Total Funding
4358
Number of Employees
$876M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eisai Inactive Page News
Fosgonimeton (also known as ATH-1017), contains an inactive molecule, ... to fosgonimeton were pain and itching at the injection site.
Co-developed by Biogen and Eisai, the therapy received accelerated ... that in many trials some participants are given an inactive placebo,...
... was approved by an institutional review board at each participating site. ... Silicon Therapeutics, Nuvalent, Inc, Eisai, Bayer, Syndax,...
Markets in Japan were closed Thursday for the spring equinox, but shares of Eisai were trading Friday morning at $54 each on the US over-the-counter market, down from $81 on Thursday at midday. On Thursday, Biogen and Eisai announced they would discontinue clinical development of aducanumab, an ...
Other Companies in Woodcliff Lake
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3122.2M | 6758 | 19% | N/A |